botensilimab,balstilimab
agenus
#wcgi2022 first oral session:
botensilimab, a next gen actla4 activating innative/adaptive immunity, plus apd1 balstilimab in mss tmb-low heavily pretreated mcrc. proof of concept evidence of responses in this immuneresistant population, restricted to pts without liver mets 
Medical Oncologist focused on #GI cancers. LOVE cats, trips, culture & RED wine.. the good one! ??????@IstTumori @FoundationGONO